Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Quest Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$2,480,124

273 payments

Through program year 2025, Quest Clinical Research is reported as receiving $2,480,124 in research payments, across 273 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $264,487 58
2024 Research $299,793 44
2023 Research $460,673 39
2022 Research $303,047 21
2021 Research $383,286 43
2020 Research $548,776 20
2019 Research $220,062 48

Breakdown

Who paid Research payments · program years 2019–2025
  1. Gilead Sciences, Inc. $729,440 19 payments
  2. GlaxoSmithKline, LLC. $485,355 90 payments
  3. Merck Sharp & Dohme Corporation $462,553 29 payments
  4. AbbVie, Inc. $333,511 19 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $194,883 6 payments
  6. ViiV Healthcare Company $73,676 15 payments
  7. CSL Behring $68,584 39 payments
  8. Roche TCRC, Inc. $45,358 9 payments
  9. Novartis Pharmaceuticals Corporation $37,423 1 payment
  10. Allergan Inc. $23,690 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. Specimen Collection Study from HIV-Infected Adults for Laboratory Research $434,121 9 payments
  2. An open label study evaluating the safety and efficacy of switching from rilpivirine/emtricitabine/tenofovir alafenamide in combination with dolutegravir, to bictegravir/emtricitabine/tenofovir alafenamide in combination with doravirine, in male HIV+ subjects > 45 years with multi-drug resistant virus and virologic suppression (documented with at least one viral load result < 50 copies per mL) during the last 6 months on current therapy $210,000 1 payment
  3. A Phase 2B, Multi-Centre, Randomized, Partially Placebo-Controlled, DO $182,957 16 payments
  4. Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Eff $179,999 30 payments
  5. POCC in NASH $149,268 31 payments
  6. A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1 $141,127 15 payments
  7. Leukapheresis on Adult Subjects with HIV-1 to Obtain Leukocytes for Testing of Virus Eradication Strategies $123,500 1 payment
  8. An open label study evaluating the safety and efficacy of switching from rilpivirine/emtricitabine/tenofovir alafenamide in combination with dolutegravir, to bictegravir/emtricitabine/tenofovir alafenamide in combination with doravirine, in male HIV+ subjects > 45 years with multi-drug resistant virus and virologic suppression (documented with at least one viral load result < 50 copies per mL) during the last 6 months on current therapy $100,000 1 payment
  9. An open label study evaluating the safety and efficacy of switching from rilpivirine/emtricitabine/tenofovir alafenamide in combination with dolutegravir, to bictegravir/emtricitabine/tenofovir alafenamide in combination with doravirine, in male HIV+ subjects > 45 years with multi-drug resistant virus and virologic suppression (documented with at least one viral load result < 50 copies per mL) during the last 6 months on current therapy $100,000 1 payment
  10. 17 B-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatme $99,810 39 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record